Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors

Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1993 • 28,274 citations

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1994 • 8,631 citations

The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels

1996 • 7,450 citations

Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia

1995 • 7,378 citations

Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels

1998 • 5,293 citations

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1998 • 5,229 citations

Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia

1987 • 3,889 citations

Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol

1999 • 3,464 citations

Prescribing Personalized Nutrition for Cardiovascular Health: Are We Ready?

2014 • 1,880 citations

Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein

1999 • 1,488 citations

Effect of Pravastatin on Outcomes after Cardiac Transplantation

1995 • 1,302 citations

Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1,2Published simultaneously in the European Heart Journal 1998;19:1434–1503 and the Journal of Hypertension (…

1998 • 1,292 citations

Current Perspectives on Statins

2000 • 1,220 citations

The Costs of Adverse Drug Events in Hospitalized Patients

1997 • 1,110 citations

Adverse Drug Events in Hospitalized Patients<subtitle>Excess Length of Stay, Extra Costs, and Attributable Mortality</subtitle>

1997 • 1,063 citations

Antiatherothrombotic Properties of Statins

1998 • 972 citations

Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition

2000 • 877 citations

Drug Treatment of Lipid Disorders

1999 • 863 citations

Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

1995 • 856 citations

Effects of Lipid Lowering by Pravastatin on Progression and Regression of Coronary Artery Disease in Symptomatic Men With Normal to Moderately Elevated Serum Cholesterol Levels

1995 • 846 citations

Lipoprotein-Associated Phospholipase A₂as an Independent Predictor of Coronary Heart Disease

2000 • 818 citations

HMG-CoA Reductase Inhibitors for Treatment of Hypercholesterolemia

1988 • 760 citations

Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

1997 • 755 citations

Cholesterol Lowering With Statin Drugs, Risk of Stroke, and Total Mortality

1997 • 737 citations

Statins do more than just lower cholesterol

1996 • 714 citations

A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)

1999 • 630 citations

Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II)

1995 • 612 citations

Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.

1994 • 602 citations

Drug-Related Morbidity and Mortality

1995 • 595 citations

Early Statin Treatment Following Acute Myocardial Infarction and 1-Year Survival

2001 • 539 citations

Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors

1997 • 524 citations

Cholesterol-Lowering Therapy in Women and Elderly Patients With Myocardial Infarction or Angina Pectoris

1997 • 516 citations

Cholesterol Lowering With Statin Drugs, Risk of Stroke, and Total Mortality

1998 • 509 citations

Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

1999 • 457 citations

HMG-CoA Reductase Inhibitors and the Risk of Fractures

2000 • 452 citations

Hyperlipidemia and Coronary Disease

1995 • 444 citations

HMG-CoA Reductase Inhibitors and the Risk of Hip Fractures in Elderly Patients

2000 • 424 citations

Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy

1990 • 422 citations

Hydroxy-Methylglutaryl–Coenzyme A Reductase Inhibition Promotes Endothelial Nitric Oxide Synthase Activation Through a Decrease in Caveolin Abundance

2001 • 418 citations

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole*

1998 • 402 citations

Inhibition of P-Glycoprotein–Mediated Drug Transport

1999 • 395 citations

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

1986 • 376 citations

Interaction between grapefruit juice and midazolam in humans*

1995 • 360 citations

Drug Interactions with Grapefruit Juice

1997 • 343 citations

Efficacy and long-term adverse effect pattern of lovastatin

1988 • 338 citations

Effects of Fluvastatin on Coronary Atherosclerosis in Patients With Mild to Moderate Cholesterol Elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])

1997 • 324 citations

HYPERLIPIDEMIA IN SOLID ORGAN TRANSPLANTATION

1997 • 317 citations

Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors*

1998 • 301 citations

Effect of itraconazole on the pharmacokinetics of atorvastatin*

1998 • 295 citations

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations*

1998 • 287 citations

Safety and Tolerability of Cholesterol Lowering With Simvastatin During 5 Years in the Scandinavian Simvastatin Survival Study

1996 • 284 citations

Atorvastatin

1997 • 281 citations

HMG-CoA Reductase Inhibitors and Myotoxicity

2000 • 279 citations

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid*

1998 • 272 citations

Inhibition of Thromboxane Biosynthesis and Platelet Function by Simvastatin in Type IIa Hypercholesterolemia

1995 • 264 citations

Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up

2002 • 260 citations

Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)

1998 • 259 citations

Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

1996 • 241 citations

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.

1990 • 240 citations

Updated New Zealand cardiovascular disease risk-benefit prediction guide

2000 • 235 citations

Rhabdomyolysis and Renal Injury With Lovastatin Use

1988 • 230 citations

Grapefruit juice–felodipine interaction: Mechanism, predictability, and effect of naringin

1993 • 230 citations

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

1999 • 226 citations

A review of medication errors and compliance in ambulant patients

1972 • 224 citations

Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients

1998 • 223 citations

Simvastatin

1990 • 219 citations

Macrolide Antibacterials

1995 • 206 citations

Biotransformation of lovastatin

1991 • 195 citations

Cholesterol Lowering and the Use of Healthcare Resources

1996 • 194 citations

Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase

1994 • 191 citations

HMG‐CoA reductase inhibitors and P‐glycoprotein modulation

2001 • 190 citations

Principles of Therapeutics

1992 • 187 citations

Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population

2000 • 186 citations

Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram*

1996 • 183 citations

Polypharmacy

1993 • 179 citations

In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

1996 • 178 citations

Disposition of pravastatin sodium, a tissue‐selective HMG‐CoA reductase inhibitor, in healthy subjects.

1990 • 174 citations

Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P-Glycoprotein-Mediated Secretion

2000 • 173 citations

The interaction of diltiazem with lovastatin and pravastatin*

1998 • 173 citations

Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor

1990 • 171 citations

Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers

1992 • 170 citations

Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors

1996 • 168 citations

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

1998 • 168 citations

Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses*

1997 • 168 citations

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1993 • 166 citations

Reduction of Albumin Excretion Rate in Normotensive Microalbuminuric Type 2 Diabetic Patients During Long-Term Simvastatin Treatment

1997 • 162 citations

Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population

1996 • 160 citations

Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine-treated kidney transplant recipients

1999 • 157 citations

Drug-related problems causing admission to a medical clinic

1981 • 151 citations

The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions.

1999 • 144 citations

Plasma Concentration Profiles of Simvastatin 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitory Activity in Kidney Transplant Recipients with and without Ciclosporin

1993 • 138 citations

Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin

1999 • 133 citations

The interaction of diltiazem with simvastatin

2000 • 132 citations

Cholesterol Lowering in the Elderly Population

1999 • 125 citations

Long-term Safety of Hepatic Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors

2000 • 125 citations

Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.

1998 • 125 citations

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors

1995 • 124 citations

Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.

1999 • 124 citations

The physiological disposition of lovastatin.

1989 • 123 citations

Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

1999 • 122 citations

Fluvastatin

1996 • 121 citations

Cytochrome P450: new nomenclature and clinical implications.

1998 • 119 citations

Rhabdomyolysis After Taking Atorvastatin With Gemfibrozil

1998 • 118 citations

Effects of long-term treatment with lovastatin on the clotting system and blood platelets

1992 • 114 citations

Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients.

1993 • 113 citations

Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations

1999 • 111 citations

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin

1991 • 110 citations

Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).

1991 • 106 citations

Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy

1999 • 106 citations

In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin*

1995 • 105 citations

Trough concentrations of cyclosporine in blood following administration with grapefruit juice

1993 • 105 citations

Rhabdomyolysis Associated with Concomitant Use of Atorvastatin and Cyclosporine

1999 • 104 citations

Inhibition by cyclosporin A of Adenosine triphosphate-dependent transport from the hepatocyte into bile

1993 • 104 citations

Metabolic interactions between mibefradil and HMG‐CoA reductase inhibitors: an in vitro investigation with human liver preparations

1999 • 99 citations

Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation

2000 • 98 citations

Drug Interactions of Lipid-Altering Drugs

1998 • 98 citations

Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells

1993 • 97 citations

Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers

2000 • 94 citations

Fluvastatin with and without niacin for hypercholesterolemia

1994 • 93 citations

Clinical Pharmacokinetics of Pravastatin

1994 • 88 citations

Drug interactions and the statins.

1999 • 86 citations

Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

1999 • 83 citations

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

1990 • 82 citations

Pharmacokinetics of Fluvastatin and Specific Drug Interactions

1993 • 82 citations

THE EFFECTS OF PRAVASTATIN ON HYPERLIPIDEMIA IN RENAL TRANSPLANT RECIPIENTS1

1992 • 80 citations

Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension

1995 • 80 citations

Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy

2000 • 79 citations

Pravastatin

1997 • 77 citations

Lovastatin-Induced Rhabdomyolysis Possibly Associated with Clarithromycin and Azithromycin

1997 • 77 citations

Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study Commentary: Causality---the Achilles' heel of observational studies Commentary: How high density lipoprotein protects against heart disease

1999 • 76 citations

Effects of pravastatin on left ventricular mass in patients with hyperlipidemia and essential hypertension

2000 • 76 citations

Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.

1989 • 75 citations

Low-dose lovastatin safely lowers cholesterol after cardiac transplantation.

1990 • 69 citations

Physiological Disposition of Hmg-Coa-Reductase Inhibitors

1990 • 68 citations

Renal Dysfunction Does Not Alter the Pharmacokinetics or LDL‐Cholesterol Reduction of Atorvastatin

1997 • 67 citations

Fluvastatin

1999 • 67 citations

Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity for Drug Interactions

1998 • 66 citations

Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil

1996 • 66 citations

Pro-apoptotic effect of fluvastatin on human smooth muscle cells

1999 • 64 citations

Exercise and diet reduce risk of diabetes, US study shows

2001 • 63 citations

Atorvastatin: A hydroxymethylglutaryl-coenzyme A reductase inhibitor

1998 • 60 citations

Effect of Food on the Bioavailability of Atorvastatin, an HMG‐CoA Reductase Inhibitor

1995 • 60 citations

Mechanisms modifying atherosclerotic disease — from lipids to vascular biology

1999 • 60 citations

Rhabdomyolysis induced by simvastatin and ketoconazole treatment.

1999 • 60 citations

Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial

1996 • 59 citations

Bayer decides to withdraw cholesterol lowering drug.

2001 • 57 citations

A case with severe rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy--a case report.

2000 • 57 citations

Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells

2000 • 57 citations

Lovastatin. Warfarin interaction

1990 • 54 citations

Differentiation of 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Inhibitors by Their Relative Lipophilicity

1999 • 54 citations

The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia

1990 • 54 citations

Influence of erythromycin pre- and co-treatment on single-dose pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin

1998 • 53 citations

Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone

1997 • 53 citations

Updated clinical safety experience with fluvastatin

1994 • 53 citations

Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil

2000 • 53 citations

Potential Interaction between Warfarin and Fluvastatin

1996 • 52 citations

Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment

1992 • 52 citations

Effect of food on pravastatin pharmacokinetics and pharmacodynamics.

1993 • 51 citations

Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin.

1997 • 51 citations

Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients

1997 • 49 citations

Drug-interaction-induced rhabdomyolysis

1996 • 49 citations

Efficacy of statin therapy: possible effect of phenytoin

1999 • 48 citations

Growth in use of statins after trials is not targeted to most appropriate patients

2000 • 47 citations

Effect of itraconazole on cerivastatin pharmacokinetics

1999 • 47 citations

Beyond lipids — the role of the endothelium in coronary artery disease

1999 • 46 citations

Preclinical and clinical pharmacology of cerivastatin

1998 • 45 citations

Atorvastatin Does Not Alter the Anticoagulant Activity of Warfarin

1997 • 45 citations

Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin

1999 • 45 citations

Pharmacokinetic interaction between propranolol and the HMG‐CoA reductase inhibitors pravastatin and lovastatin.

1991 • 43 citations

Atorvastatin Calcium: An Addition to HMG‐CoA Reductase Inhibitors

1997 • 43 citations

Evaluating patients with renal failure for renal artery stenosis with gadolinium-enhanced magnetic resonance angiography

1999 • 42 citations

Choosing the Right Lipid-Regulating Agent

1996 • 41 citations

Antihyperlipidaemic Agents

1994 • 40 citations

The influence of pretreatment lew density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trials

1995 • 39 citations

Lovastatin

1990 • 38 citations

Combination Therapy with Low‐Dose Lovastatin and Niacin Is as Effective as Higher‐Dose Lovastatin

1996 • 37 citations

Clinical implications of the biopharmaceutical properties of fluvastatin

1994 • 36 citations

The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia

1990 • 36 citations

Interaction between lovastatin and cyclosporine A after heart and kidney transplantation

1999 • 36 citations

Safety of combined pravastatin-gemfibrozil therapy

1994 • 35 citations

Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia

1995 • 35 citations

Foreigners flock to Cuba for medical care

2001 • 34 citations

Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation

1991 • 34 citations

Enhanced cholesterol reduction by simvastatin in diltiazem‐treated patients

1999 • 32 citations

Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P-glycoprotein mediated transport in liver.

1994 • 31 citations

Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine

2000 • 31 citations

Extending Therapy Options in Treating Lipid Disorders

1998 • 31 citations

Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine

1999 • 30 citations

Adverse Drug Events in Hospitalized Patients

1997 • 30 citations

Lovastatin-Induced Rhabdomyolysis in the Absence of Concomitant Drugs

1992 • 30 citations

A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine

1995 • 29 citations

No Pharmacokinetic or Pharmacodynamic Interaction Between Rivastatin and Warfarin

1995 • 28 citations

US spending on prescription drugs rose by 19% in 2000.

2001 • 27 citations

The Effect of Converting from Pravastatin to Simvastatin on the Pharmacodynamics of Warfarin

1999 • 27 citations

Influence of cholestyramine on the pharmacokinetics of cerivastatin.

1997 • 26 citations

Drug points: Pravastatin: interaction with oral anticoagulant?

1996 • 26 citations

Differential metabolism of statins: importance in drug-drug interactions

1999 • 25 citations

Effects of felbamate on the pharmacokinetics of the monohydroxy and dihydroxy metabolites of oxcarbazepine

1995 • 25 citations

Approaches to The Treatment of Hyperlipidemia in the Solid Organ Transplant Recipient

1995 • 25 citations

EFFECT OF FLUVASTATIN ON LIPOPROTEIN PROFILES IN TREATING RENAL TRANSPLANT RECIPIENTS WITH DYSLIPOPROTEINEMIA

1995 • 24 citations

‘Fire and forget?’ — pharmacological considerations in coronary care

1999 • 23 citations

The interaction of fluvastatin and cyclosporin A in renal transplant patients.

1995 • 22 citations

Atorvastatin does not Produce a Clinically Significant Effect on the Pharmacokinetics of Terfenadine

1998 • 22 citations

Drug Interaction between Simvastatin and Cholestyramine in Vitro and in Vivo.

1996 • 20 citations

Statins are the new aspirin, Oxford researchers say

2001 • 18 citations

109 Lack of pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin

1997 • 18 citations

Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics

1999 • 18 citations

Effects of Simvastatin and Pravastatin on Hyperlipidemia and Cyclosporin Blood Levels in Renal Transplant Recipients

1999 • 16 citations

Effect of Orlistat, a Novel Anti-Obesity Agent, on the Pharmacokinetics and Pharmacodynamics of Pravastatin in Patients with Mild Hypercholesterolaemia

1999 • 16 citations

Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events

1999 • 16 citations

The Use of HMG-CoA Reductase Inhibitors to Prevent Accelerated Graft Atherosclerosis in Heart Transplant Patients

1997 • 16 citations

Pharmacodynamics of new HMG-CoA reductase inhibitor ZD4522 in patients with primary hypercholesterolaemia

2000 • 15 citations

Biotransformation of lovastatin—III

1990 • 15 citations

Simvastatin

1997 • 15 citations

Effects of Atorvastatin, an HMG‐CoA Reductase Inhibitor, on Hepatic Oxidative Metabolism of Antipyrine

1996 • 14 citations

Lack of mutual pharmacokinetic interaction between cerivastatin, a new HMG-CoA reductase inhibitor, and digoxin in healthy normocholesterolemic volunteers

1999 • 13 citations

Bayer faces potential fine over cholesterol lowering drug

2001 • 13 citations

Influence of lacidipine on plasma aldosterone production in hypertensive subjects

1993 • 10 citations

Low-dose lovastatin in hyperlipidemic kidney graft recipients with cyclosporine A.

1992 • 9 citations

Lovastatin treatment of hyperlipidemia in kidney transplant recipients on cyclosporine immunosuppression.

1994 • 9 citations

111 Pharmacokinetics of cerivastatin administration with and without food in the morning and evening

1997 • 8 citations

Effects of HMG CoA Reductase Inhibitors on Warfarin Binding

1991 • 7 citations

Fluvastatin in renal transplantation

1997 • 6 citations

Effects of Pravastatin on Cholesterol Metabolism in Watanabe Heritable Hyperlipidemic Rabbits.

1992 • 5 citations

In brief

2001 • 4 citations

Grapefruit juice increases serum simvastatin and atorvastatin but not pravastatin

1999 • 4 citations

Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy

1999 • 3 citations